We now effectively authorize Health Canada to administratively determine what the user fees should be, and these fees are reflected in the full cost of the services provided. If a pharmaceutical manufacturer contests the fees being charged—they might consider them out of line, out of whack, or not reflective—that company's recourse would not be to the minister, I take it, or would the minister have the ability to overrule the department?
On May 9th, 2017. See this statement in context.